Ocular Therapeutix (OCUL) Receivables (2013 - 2026)

Ocular Therapeutix's Receivables history runs 14 years deep, the most recent figure standing at $24.3 million for Q1 2026.

• On a quarterly basis, Receivables fell 3.47% year-over-year to $24.3 million in Q1 2026; TTM through Mar 2026 was $24.3 million, a 3.47% decrease from a year earlier, with the FY2025 full-year figure at $30.6 million, down 5.37% from the prior year.
• Receivables retreated to $24.3 million in Q1 2026 per OCUL's latest filing, from $30.6 million in the prior quarter.
• Across five years, Receivables topped out at $32.4 million in Q4 2024 and bottomed at $19.8 million in Q3 2022.
• The 5-year median for Receivables is $26.2 million (2023), against an average of $26.1 million.
• Across the five-year window, Receivables jumped 70.25% in 2022 and dropped 8.98% in 2023, its largest moves.
• Year by year, Receivables stood at $21.3 million in 2022, then gained by 22.76% to $26.2 million in 2023, then grew by 23.72% to $32.4 million in 2024, then slipped by 5.37% to $30.6 million in 2025, then fell by 20.56% to $24.3 million in 2026.
• Per Business Quant, the three latest OCUL Receivables figures stand at $24.3 million (Q1 2026), $30.6 million (Q4 2025), and $30.8 million (Q3 2025).